ACE2 and Myocardial fibrosis: Paradoxically, however, RASS inhibitors cause an augmentation of the viral entry receptor ACE2, which may give rise to the toxicity of SARS-CoV-2 in the heart and ultimately accelerate the development of myocardial fibrosis.